Description
The INVOKE-2 failure raised questions about whether TREM2 enhancement is beneficial in early versus late disease stages, but this timing-dependent efficacy remains unresolved. Understanding this could explain clinical trial failures and guide future study design.
Source: Debate session sess_sda-2026-04-01-001 (Analysis: sda-2026-04-01-001)
Evidence summary
Resolved by hypothesis h-var-e2b5a7e7db: GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance. Score: 0.964. Supporting PMIDs: 19449329, 23431156, 26282667, 40994429, 40796363.